Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.
Noura J ChoudhuryAlex MakhninYosef Y TobiRobert M DalyIsabel R PreeshagulAfsheen N IqbalLinda S AhnSara A HayesGlenn HellerMark G KrisGregory J RielyHelena A YuPublished in: JCO precision oncology (2021)
In the first trial evaluating a second-generation EGFR TKI after first-line third-generation osimertinib, we found that dacomitinib after disease progression on osimertinib has limited benefit.